

TABLE OF CONTENTS

| Contents | Page No. |
|---|-------------------|
| Abstract | i-vii |
| Declaration | |
| Certificate | |
| Acknowledgements | viii-ix |
| Table of Contents | x-xix |
| List of Tables | xx-xxii |
| List of Figures | xxiii-xxix |
| List of Symbols and Abbreviations | xxx-xxxv |
| | |
| CHAPTER-I | |
| INTRODUCTION | 1-72 |
| 1.1 Introduction..... | 1 |
| 1.2 Taxonomic classification and geographical distribution of snakes..... | 2 |
| 1.3 Snakebite: A tropical health hazard..... | 3 |
| 1.3.1 Global burden of snakebite..... | 4 |
| 1.3.2 Indian scenario of snakebite..... | 4 |
| 1.4 The Indian Spectacled Cobra (<i>Naja naja</i>)..... | 7 |
| 1.4.1 Taxonomic classification..... | 7 |
| 1.4.2 Distinctive features and description..... | 8 |
| 1.4.3 Habitat and geographical distribution..... | 8 |
| 1.4.4 Venom apparatus of <i>N. naja</i> | 9 |
| 1.4.5 Pathophysiology of cobra envenomation..... | 10 |
| 1.5 A brief account on <i>N. naja</i> venom..... | 11 |
| 1.5.1 Composition of <i>N. naja</i> venom..... | 11 |
| 1.5.2 Differential composition of Indian cobra (<i>Naja naja</i>) venom: A biochemical approach..... | 13 |
| 1.5.3 Deciphering the composition of Indian cobra (<i>Naja naja</i>) venom: A proteomic approach..... | 14 |
| 1.6 The blood coagulation cascade to understand the anticoagulant mechanism of <i>N. naja</i> venom proteins..... | 15 |
| 1.7 Snake venom phospholipase A ₂ enzymes..... | 17 |
| 1.7.1 Classification of snake venom PLA ₂ enzymes..... | 18 |
| 1.7.1.1 Group I PLA ₂ enzymes..... | 18 |
| 1.7.1.2 Group II PLA ₂ enzymes..... | 19 |
| 1.7.2 Structure of PLA ₂ enzymes..... | 19 |
| 1.7.3 Catalytic property of snake venom PLA ₂ enzymes..... | 21 |
| 1.7.4 Pharmacological effects of snake venom PLA ₂ enzymes..... | 23 |
| 1.7.4.1 Myotoxic effect of PLA ₂ enzymes..... | 23 |
| 1.7.4.2 Anticoagulant effect of PLA ₂ enzymes..... | 25 |
| 1.7.4.2.1 Types of anticoagulant PLA ₂ | 25 |
| 1.7.4.2.2 Mechanism of anticoagulant action..... | 25 |
| 1.7.5 Pharmacological site and target specificity of snake venom PLA ₂ | 26 |
| 1.7.5.1 Pharmacological site for myotoxic PLA ₂ | 26 |
| 1.7.5.2 Pharmacological site for anticoagulant PLA ₂ | 27 |
| 1.7.6 Evolution of snake venom PLA ₂ enzymes..... | 27 |

TABLE OF CONTENTS

| Contents | Page No. |
|--|-----------------|
| 1.8 Snake venom toxin synergism and PLA ₂ complexes..... | 28 |
| 1.8.1 Snake venom toxin synergism..... | 28 |
| 1.8.2 Protein complexes of snake venom PLA ₂ enzymes..... | 30 |
| 1.8.2.1 Covalent complexes of snake venom PLA ₂ | 30 |
| 1.8.2.2 Non-covalent complexes of snake venom PLA ₂ | 31 |
| 1.9 Thrombosis associated cardiovascular disorders and their treatments..... | 32 |
| 1.9.1 Thrombosis leads to cardiovascular diseases..... | 32 |
| 1.9.2 Treatment for CVDs and limitations of commercial drugs..... | 33 |
| 1.10 Therapeutic application of snake venom anticoagulant proteins..... | 35 |
| 1.11 Peptides as drugs: Emergence and advantages..... | 37 |
| 1.12 Gap in the study..... | 39 |
| 1.13 Aims and objectives of the present study..... | 39 |
| Bibliography..... | 40 |

CHAPTER II**REVIEW OF LITERATURE****73-107**

| | |
|---|----|
| 2.1 A brief review on anticoagulant proteins from cobra venom..... | 73 |
| 2.1.1 Anticoagulant phospholipase A ₂ enzymes..... | 73 |
| 2.1.1.1 Enzymatic mechanism of anticoagulant action of cobra venom PLA ₂ enzymes..... | 74 |
| 2.1.1.2 Non-enzymatic mechanism of anticoagulant action of cobra venom PLA ₂ enzymes..... | 74 |
| 2.1.1.2.1 Cobra venom PLA ₂ thrombin inhibitors..... | 75 |
| 2.1.1.2.2 Cobra venom PLA ₂ factor Xa inhibitors..... | 76 |
| 2.1.2 Anticoagulant metallo-proteinases of cobra venom..... | 77 |
| 2.1.3 Other anticoagulant and antiplatelet proteins of cobra venom..... | 80 |
| 2.2 A brief appraisal on peptide therapeutics developed from snake venom for treatment of cardiovascular diseases..... | 81 |
| 2.3 A brief account on cytotoxic PLA ₂ s and their complexes in cobra venom..... | 83 |
| 2.4 A brief account on cobra venom myotoxic PLA ₂ s..... | 87 |
| 2.5 Understanding the mechanism of snake venom PLA ₂ -induced myotoxicity..... | 88 |
| Bibliography..... | 92 |

CHAPTER III**MATERIALS AND METHODS****108-156**

| | |
|--|-----|
| 3.1 Materials..... | 108 |
| 3.1.1 Venom and antivenom..... | 108 |
| 3.1.2 Chromatographic matrices, cell lines, and cell culture reagents..... | 108 |
| 3.1.3 Coagulation factors and fine chemicals..... | 109 |
| 3.1.4 Analytical grade chemicals and kits..... | 109 |
| 3.1.5 Raising polyclonal antibodies against purified PLA ₂ isolated from <i>N. naja</i> venom..... | 109 |
| 3.1.6 Animals and housing conditions..... | 110 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|-----------------|
| 3.2 Methods..... | 110 |
| 3.2.1 Purification of an anticoagulant protein and its complex from eastern India <i>N. naja</i> venom..... | 110 |
| 3.2.1.1 Cation-exchange chromatography of <i>N. naja</i> venom..... | 110 |
| 3.2.1.2 Size-exclusion chromatography of the most anticoagulant fraction... | 111 |
| 3.2.2 Determination of homogeneity, purity, and molecular weight of the anticoagulant phospholipase A ₂ | 111 |
| 3.2.2.1 Reversed-phase HPLC of the anticoagulant PLA ₂ | 111 |
| 3.2.2.2 Analysis of purity and molecular mass of the anticoagulant PLA ₂ by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)..... | 111 |
| 3.2.2.3 Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-ToF-MS) analysis of the anticoagulant PLA ₂ | 113 |
| 3.2.3 Biophysical characterization..... | 113 |
| 3.2.3.1 Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis..... | 113 |
| 3.2.3.1.1 In-solution and in-gel trypsin digestion of proteins..... | 113 |
| 3.2.3.1.2 LC-MS/MS analysis of the tryptic peptides and identification of protein..... | 114 |
| 3.2.3.2 Determination of secondary structure..... | 115 |
| 3.2.4 Determination of venom PLA ₂ cognate complex(es) and identification of its components | 115 |
| 3.2.4.1 Two-dimensional SDS-PAGE (2D SDS-PAGE) of <i>N. naja</i> venom.. | 115 |
| 3.2.4.2 Immunoblotting of 2D SDS-PAGE separated EI NnV..... | 116 |
| 3.2.4.3 Identification of components of PLA ₂ -cognate complex..... | 117 |
| 3.2.4.3.1 RP-HPLC of PLA ₂ -cognate complex..... | 117 |
| 3.2.4.3.2 In-sol trypsin digestion of Nn(N)CM2 and its RP-HPLC fractions followed by LC-MS/MS..... | 117 |
| 3.2.4.3.3 In-gel trypsin digestion of anti-PLA ₂ antibody detected 2D SDS-PAGE spots followed by LC-MS/MS..... | 117 |
| 3.2.4.3.4 Determination of relative abundance and stoichiometry of venom proteins in PLA ₂ cognate complex..... | 118 |
| 3.2.4.4 One dimensional (1D) SDS-PAGE to confirm complex formation by NnV PLA ₂ | 119 |
| 3.2.5 Biochemical characterizations..... | 119 |
| 3.2.5.1 Estimation of protein content..... | 119 |
| 3.2.5.2 Phospholipase A ₂ activity assay..... | 119 |
| 3.2.5.2.1 Turbidometric method..... | 119 |
| 3.2.5.2.2 Secretory PLA ₂ assay kit..... | 120 |
| 3.2.5.3 Substrate specificity and enzyme kinetics..... | 120 |
| 3.2.5.4 Effect of pH and temperature on enzyme activity..... | 120 |
| 3.2.5.5 Effect of chemical inhibitors and heparin on enzymatic and anticoagulant activities..... | 121 |
| 3.2.5.6 Neutralization by commercial antivenom..... | 121 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|----------|
| 3.2.6 <i>In silico</i> interaction of PLA ₂ with coagulation factor(s) docking analysis and peptide designing..... | 122 |
| 3.2.6.1 Structure prediction of the purified PLA ₂ | 122 |
| 3.2.6.2 Docking analysis with thrombin and factor Xa..... | 122 |
| 3.2.6.3 Designing of anticoagulant peptides and their synthesis..... | 122 |
| 3.2.6.4 Physico-chemical characterization and <i>in silico</i> antigenicity determination of the synthetic peptides..... | 122 |
| 3.2.6.5 Structure prediction of the 7-mer anticoagulant peptide..... | 123 |
| 3.2.6.6 Docking of 7-mer peptide with thrombin and FXa..... | 123 |
| 3.2.7 Preparation of peptide solutions..... | 123 |
| 3.2.8 <i>In vitro</i> effect of NnV PLA ₂ and synthetic peptide on coagulation factors (thrombin, factor Xa, and prothrombin)..... | 123 |
| 3.2.8.1 Effect on thrombin..... | 123 |
| 3.2.8.1.1 Effect on amidolytic activity of thrombin..... | 123 |
| 3.2.8.1.2 Effect on fibrinogen clotting activity of thrombin..... | 124 |
| 3.2.8.1.3 Kinetics of thrombin inhibition..... | 124 |
| 3.2.8.1.4 Effect of inhibitors on thrombin inhibition..... | 125 |
| 3.2.8.1.4.1 Effect of heparin and/or antithrombin on inhibition of amidolytic activity of thrombin by PLA ₂ and/or peptide..... | 125 |
| 3.2.8.1.4.2 Effect of heparin on inhibition of fibrinogen clotting activity of thrombin by PLA ₂ | 126 |
| 3.2.8.1.4.3 Effect of <i>p</i> -BPB on inhibition of amidolytic activity of thrombin by PLA ₂ | 126 |
| 3.2.8.2 Effect on factor Xa..... | 127 |
| 3.2.8.2.1 Effect on amidolytic activity of FXa..... | 127 |
| 3.2.8.2.2 Effect on prothrombin activation by FXa..... | 127 |
| 3.2.8.2.3 Kinetics of FXa inhibition..... | 128 |
| 3.2.8.3 Effect of 7-mer peptide on prothrombin: An amidolytic assay to determine thrombin formation..... | 128 |
| 3.2.9 Protein-protein interaction studies..... | 129 |
| 3.2.9.1 Spectrofluorometry assay of interaction of purified PLA ₂ / peptide with phospholipid and coagulation factors..... | 129 |
| 3.2.9.1.1 Interaction with PC..... | 129 |
| 3.2.9.1.2 Interaction with thrombin and FXa..... | 129 |
| 3.2.9.2 Surface plasmon resonance to determine the binding with thrombin..... | 130 |
| 3.2.10 Pharmacological characterization..... | 130 |
| 3.2.10.1 Whole blood clotting assay..... | 130 |
| 3.2.10.2 Plasma clotting assays..... | 130 |
| 3.2.10.2.1 Screening of anticoagulant activity of peptides..... | 130 |
| 3.2.10.2.2 Plasma re-calcification assay..... | 131 |
| 3.2.10.2.3 Effect of time on re-calcification of PPP..... | 131 |
| 3.2.10.2.4 Prothrombin time (PT) assay..... | 131 |
| 3.2.10.2.5 Activated partial thromboplastin time (APTT) assay..... | 132 |
| 3.2.10.2.6 Thrombin time (TT) assay..... | 132 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|-----------------|
| 3.2.10.2.7 Determination of fatty acid release from plasma..... | 133 |
| 3.2.10.3 Platelet modulating activity..... | 133 |
| 3.2.10.3.1 Isolation of platelet rich plasma and washed platelets..... | 133 |
| 3.2.10.3.2 Effect on PRP or washed platelets..... | 133 |
| 3.2.10.3.3 Effect of phospholipids on PLA ₂ induced platelet deaggregation..... | 134 |
| 3.2.10.3.4 Effect of heparin, <i>p</i> -BPB, and antivenom on platelet modulating property..... | 134 |
| 3.2.10.3.5 Effect on collagen-induced platelet aggregation..... | 135 |
| 3.2.10.3.6 Effect on thrombin-induced platelet aggregation..... | 135 |
| 3.2.10.3.7 Platelet binding assay..... | 135 |
| 3.2.10.4 Direct and indirect hemolytic activity assay..... | 136 |
| 3.2.10.5 Antibacterial activity assay..... | 136 |
| 3.2.10.6 <i>In vitro</i> cell-cytotoxicity assay..... | 137 |
| 3.2.10.6.1 Effect on platelet viability..... | 137 |
| 3.2.10.6.2 Effect on cancerous and normal mammalian cell lines..... | 137 |
| 3.2.10.6.3 Flow cytometry analysis to determine the cell cycle kinetics. | 138 |
| 3.2.10.6.4 Effect on rat skeletal muscle cells or myoblasts..... | 138 |
| 3.2.10.6.4.1 Culturing and partial differentiation of rat myoblasts... | 138 |
| 3.2.10.6.4.2 Bright field imaging and MTT-based myoblasts viability assay..... | 138 |
| 3.2.10.6.4.3 Effect on myoblast morphology..... | 139 |
| 3.2.10.6.4.4 Assessment of serum CK and LDH..... | 139 |
| 3.2.10.6.5 Neutralization of PLA ₂ cognate complex-induced cytotoxicity by polyvalent antivenom and anti-PLA ₂ antibody..... | 139 |
| 3.2.10.6.6 Inhibition of PLA ₂ cognate complex-induced cytotoxicity by chemical modification of His47 residue..... | 140 |
| 3.2.11 Binding and internalization of purified PLA ₂ to myoblasts..... | 140 |
| 3.2.11.1 Determination of binding of purified EI NnV PLA ₂ and Nn(N)CM2 to L6 myoblasts by ELISA..... | 140 |
| 3.2.11.2 Immunofluorescence assay to determine the time-dependent binding followed by internalization of purified PLA ₂ in L6 myoblasts..... | 141 |
| 3.2.11.3 Confocal microscopy to determine internalization of fluorescein isothiocyanate (FITC)-conjugated purified PLA ₂ in myoblasts..... | 142 |
| 3.2.12 Binding of purified PLA ₂ and its cognate complex [Nn(N)CM2] to myoblast membrane proteins..... | 142 |
| 3.2.12.1 Isolation of myoblast membrane proteins..... | 142 |
| 3.2.12.2 Immunological assays to determine binding of purified PLA ₂ to L6 myoblast membrane proteins (L6MP)..... | 143 |
| 3.2.12.2.1 ELISA to determine binding to L6MP..... | 143 |
| 3.2.12.2.2 Immunoblot analysis of L6MP binding to purified PLA ₂ and Nn(N)CM2..... | 143 |

TABLE OF CONTENTS

| Contents | Page No. |
|--|-----------------|
| 3.2.12.2.3 LC-MS/MS to identify the NnPLA ₂ -I binding L6MP..... | 144 |
| 3.2.12.3 Isolation and purification of PLA ₂ -binding L6MP..... | 144 |
| 3.2.12.3.1 Affinity purification of PLA ₂ binding L6MP..... | 144 |
| 3.2.12.3.2 RP-HPLC and identification of PLA ₂ binding L6MP..... | 145 |
| 3.2.13 <i>In silico</i> analysis to determine interaction of PLA ₂ and its cognate complex [Nn(N)CM2 fraction] with coagulation factors and vimentin..... | 145 |
| 3.2.13.1 Structure prediction of interacting proteins/peptides..... | 145 |
| 3.2.13.2 Docking analysis with vimentin and predicting free-energy of interaction..... | 146 |
| 3.2.14 Validation of <i>in silico</i> docking results..... | 146 |
| 3.2.14.1 ELISA to determine binding of purified PLA ₂ to vimentin..... | 146 |
| 3.2.14.2 Spectrofluorometry analysis to determine dose- and time-dependent binding of purified PLA ₂ and its cognate complex [Nn(N)CM2] to vimentin..... | 146 |
| 3.2.15 Assessment of <i>in vivo</i> toxicity and therapeutic potential of the purified PLA ₂ and 7-mer anticoagulant custom peptide..... | 147 |
| 3.2.15.1 Toxicity assessment..... | 147 |
| 3.2.15.2 Histological study of major organs..... | 148 |
| 3.2.15.3 Assessment of <i>in vivo</i> anticoagulant activity..... | 148 |
| 3.2.15.4 Assessment of <i>in vivo</i> antithrombotic potential..... | 148 |
| Bibliography..... | 149 |

CHAPTER IV

RESULTS AND DISCUSSION: Characterization of an acidic phospholipase A₂ purified from Indian cobra (*Naja naja*) venom, and assessment of *in vivo* toxicity, and anticoagulant activity of this anticoagulant PLA₂ in a rodent model

157-205

| | |
|--|-----|
| 4.1 Brief Introduction..... | 157 |
| 4.2 Results..... | 158 |
| 4.2.1 Isolation and purification of an anticoagulant PLA ₂ from <i>N. naja</i> venom... | 158 |
| 4.2.1.1 Cation-exchange chromatography of <i>N. naja</i> venom..... | 158 |
| 4.2.1.2 Gel filtration chromatography of NnCM1..... | 159 |
| 4.2.2 RP-HPLC of NnCM1GF5..... | 161 |
| 4.2.3 Determination of molecular weight of NnPLA ₂ -I..... | 161 |
| 4.2.4 LC-MS/MS to identify the purified protein..... | 163 |
| 4.2.5 Circular dichroism (CD) spectroscopy for secondary structure determination of NnPLA ₂ -I..... | 163 |
| 4.2.6 Biochemical characterization..... | 164 |
| 4.2.6.1 Dose-dependent phospholipase A ₂ activity of NnPLA ₂ -I..... | 164 |
| 4.2.6.2 Substrate specificity of NnPLA ₂ -I..... | 165 |
| 4.2.6.3. Kinetics of PC hydrolysis by NnPLA ₂ -I..... | 165 |
| 4.2.6.4 Effect of temperature and pH on catalytic activity of NnPLA ₂ -I..... | 166 |
| 4.2.7 Pharmacological characterization..... | 167 |
| 4.2.7.1 Anticoagulant activity of NnPLA ₂ -I..... | 167 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|-----------------|
| 4.2.7.1.1 Effect of NnPLA ₂ -I on re-calcification time of plasma and its comparison with commercial anticoagulants..... | 167 |
| 4.2.7.1.2 Effect of NnPLA ₂ -I on PT and APTT of PPP..... | 167 |
| 4.2.7.2 Effect of NnPLA ₂ -I on coagulation factors..... | 169 |
| 4.2.7.2.1 Effect of NnPLA ₂ -I on fibrinogen clotting time of thrombin... | 169 |
| 4.2.7.2.2 Effect of NnPLA ₂ -I on amidolytic activity of thrombin..... | 171 |
| 4.2.7.2.3 Kinetics of thrombin inhibition by NnPLA ₂ -I..... | 172 |
| 4.2.7.2.4 Effect on amidolytic and prothrombin activation property of factor Xa..... | 173 |
| 4.2.7.3 Effect on other serine proteases..... | 175 |
| 4.2.7.4 Platelet modulating activity of NnPLA ₂ -I..... | 175 |
| 4.2.7.4.1 Effect of NnPLA ₂ -I on platelet rich plasma (PRP) and washed platelets..... | 175 |
| 4.2.7.4.2 Effect of NnPLA ₂ -I on collagen- and thrombin-induced platelet aggregation..... | 176 |
| 4.2.7.4.3 Neutralization and inhibition of antiplatelet and platelet binding property of NnPLA ₂ -I..... | 176 |
| 4.2.7.5 Hemolytic activity, cell cytotoxicity, and antibacterial activity..... | 178 |
| 4.2.8 Inhibition and neutralization of catalytic and anticoagulant activities of NnPLA ₂ -I..... | 179 |
| 4.2.8.1 Effect of chemical inhibitors and heparin on the activities of NnPLA ₂ -I..... | 179 |
| 4.2.8.2 Effect of heparin on thrombin inhibition by NnPLA ₂ -I..... | 180 |
| 4.2.8.3 Neutralization of catalytic and anticoagulant activities of NnPLA ₂ -I by commercial antivenoms..... | 182 |
| 4.2.9 Interaction with phospholipids and coagulation factor(s)..... | 183 |
| 4.2.9.1 <i>In silico</i> structure prediction and interaction with thrombin..... | 183 |
| 4.2.9.1.1 Structure prediction of NnPLA ₂ -I..... | 183 |
| 4.2.9.1.2 Docking of NnPLA ₂ -I with human thrombin..... | 184 |
| 4.2.9.2 Spectrofluorometry assay of interaction of NnPLA ₂ -I with PC..... | 185 |
| 4.2.9.3 Spectrofluorometry assay of interaction of NnPLA ₂ -I with FXa and thrombin | 185 |
| 4.2.10 Assessment of <i>in vivo</i> toxicity and therapeutic potential of NnPLA ₂ -I..... | 187 |
| 4.2.10.1 Assessment of lethality and behavioral parameters of rats..... | 187 |
| 4.2.10.2 Effect on serological parameters of blood..... | 188 |
| 4.2.10.3 Effect on blood parameters..... | 188 |
| 4.2.10.4 Effect on histological parameters..... | 188 |
| 4.2.10.5 Assessment of <i>in vivo</i> anticoagulant property of NnPLA ₂ -I..... | 191 |
| 4.3 Discussion..... | 193 |
| Bibliography..... | 198 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|----------------|
| CHAPTER V | |
| RESULTS AND DISCUSSION: Study on <i>in vitro</i> myotoxicity (cytotoxicity towards rat myoblasts) of NnPLA₂-I and its acidic cognate complex on rat myotubes and their neutralization by commercial polyvalent anti-snake venom and anti-NnPLA₂-I antibody | 206-265 |
| 5.1 Brief introduction..... | 206 |
| 5.2 Results..... | 207 |
| 5.2.1 2D SDS-PAGE analysis of eastern India <i>N. naja</i> venom followed by western blot analysis to detect complex formation by NnPLA ₂ -I..... | 207 |
| 5.2.2 Cation-exchange chromatography of eastern India NnV..... | 208 |
| 5.2.3 LC-MS/MS of Nn(N)CM2 and anti-NnPLA ₂ -I antibody recognized regions of 2D SDS-PAGE of NnV..... | 209 |
| 5.2.4 Determination of stoichiometry of venom proteins in the cognate complex..... | 216 |
| 5.2.5 Isolation and identification of individual components of Nn(N)CM2 by RP-HPLC and LC-MS/MS analysis..... | 216 |
| 5.2.6 One-dimensional SDS-PAGE analysis of Nn(N)CM2..... | 218 |
| 5.2.7 Determination of molecular mass of Nn(N)CM2 by gel filtration chromatography..... | 219 |
| 5.2.8 Quantitation of NnPLA ₂ -I in Nn(N)CM2 by ELISA..... | 220 |
| 5.2.9 Cytotoxicity of PLA ₂ and its cognate complex against the mammalian and bacterial cells..... | 221 |
| 5.2.10 Assessment of release of creatine kinase and lactate dehydrogenase from NnPLA ₂ -I cognate complex treated L6 myoblasts..... | 222 |
| 5.2.11 Cytotoxicity of NnPLA ₂ -I cognate complex and its individual components on rat myoblasts..... | 223 |
| 5.2.11.1 Determination of cytotoxicity by MTT assay..... | 223 |
| 5.2.11.2 Determination of cytotoxicity by bright field microscopy..... | 225 |
| 5.2.11.3 Determination of cytotoxicity by acridine orange / ethidium bromide staining..... | 227 |
| 5.2.12 ELISA to determine binding of NnPLA ₂ -I to rat myoblasts..... | 228 |
| 5.2.13 Time-dependent internalization of NnPLA ₂ -I in rat myoblasts..... | 228 |
| 5.2.13.1 Fluorescence microscopy to determine internalization of NnPLA ₂ -I..... | 228 |
| 5.2.13.2 Confocal microscopy to determine internalization of FITC-conjugated NnPLA ₂ -I..... | 229 |
| 5.2.14 Binding of NnPLA ₂ -I and its cognate complex to rat myoblast membrane proteins (L6MP)..... | 231 |
| 5.2.14.1 ELISA showed binding of NnPLA ₂ -I and its cognate complex to L6MP..... | 231 |
| 5.2.14.2 Immunoblot analysis confirmed binding of NnPLA ₂ -I and its cognate complex to L6MP..... | 231 |
| 5.2.15 RP-HPLC of affinity purified L6MP..... | 233 |
| 5.2.16 ELISA to determine the binding of NnPLA ₂ -I to L6RP1..... | 234 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|-----------------|
| 5.2.17 Identification of NnPLA ₂ -I binding L6MP by LC-MS/MS analysis..... | 234 |
| 5.2.18 Spectrofluorometry analysis to determine binding of NnPLA ₂ -I and its cognate complex to vimentin..... | 237 |
| 5.2.18.1 Dose- and time-dependent binding of NnPLA ₂ -I to vimentin..... | 237 |
| 5.2.18.2 Dose- and time-dependent binding of NnPLA ₂ -I cognate complex to vimentin..... | 239 |
| 5.2.19 <i>In silico</i> analysis to demonstrate binding of NnPLA ₂ -I and its cognate complex to the rod region of vimentin..... | 240 |
| 5.2.19.1 Docking of NnPLA ₂ -I with different chains of vimentin..... | 240 |
| 5.2.19.2 Docking of CTx, LNTx, and NGF with vimentin..... | 244 |
| 5.2.19.3 Docking of NnPLA ₂ -I with CTx, LNTx, and NGF to form a cognate complex..... | 246 |
| 5.2.19.4 Docking of 3FTx-NnPLA ₂ -I and 3FTx-NGF-NnPLA ₂ -I complexes with vimentin..... | 248 |
| 5.2.20 ELISA to determine NnPLA ₂ -I does not bind to tail region of vimentin... | 251 |
| 5.3 Discussion..... | 252 |
| Bibliography..... | 257 |

Chapter VI

RESULTS AND DISCUSSION: Designing, characterization, and elucidation of mechanism of action of a 7-mer peptide from the anticoagulant region of NnPLA₂-I, and assessment of *in vivo* toxicity, anticoagulant and antithrombotic activity of this anticoagulant peptide in a rodent model **266-300**

| | |
|--|-----|
| 6.1 Brief Introduction..... | 266 |
| 6.2 Results..... | 267 |
| 6.2.1 Design and synthesis of peptides corresponding to thrombin-binding regions of NnPLA ₂ -I..... | 267 |
| 6.2.2 Determination of physico-chemical properties of the synthesized peptides | 267 |
| 6.2.3 Docking of ACR1-12 with thrombin..... | 268 |
| 6.2.4 Screening of anticoagulant activity of ACR1-12..... | 268 |
| 6.2.5 Anticoagulant activity of ACR9..... | 269 |
| 6.2.5.1 Effect of ACR9 on re-calcification time of whole blood and PPP.... | 269 |
| 6.2.5.2 Effect of ACR9 on PT, APTT, and TT of PPP..... | 270 |
| 6.2.6 Thrombin inhibition by ACR9..... | 271 |
| 6.2.6.1 Effect on fibrinogen clotting time of thrombin..... | 271 |
| 6.2.6.2 Effect on amidolytic activity of thrombin..... | 272 |
| 6.2.6.3 Kinetics of thrombin inhibition by ACR9..... | 274 |
| 6.2.7 Factor Xa inhibition by ACR9..... | 275 |
| 6.2.7.1 Effect on prothrombin activation by FXa..... | 275 |
| 6.2.7.2 Effect on amidolytic activity of FXa..... | 276 |
| 6.2.7.3 Kinetics of FXa inhibition by ACR9..... | 278 |
| 6.2.8 Analysis of <i>in silico</i> binding of ACR9 to thrombin and FXa..... | 279 |
| 6.2.8.1 Determination of structure of ACR9..... | 279 |
| 6.2.8.2 Docking of ACR9 with thrombin..... | 280 |
| 6.2.8.3 Docking of ACR9 with FXa..... | 281 |

TABLE OF CONTENTS

| Contents | Page No. |
|---|-----------------|
| 6.2.9 Determination of antigenicity of ACR9..... | 282 |
| 6.2.10 Spectrofluorometry interaction of ACR9 with thrombin and FXa..... | 282 |
| 6.2.10.1 Interaction with thrombin..... | 282 |
| 6.2.10.2 Interaction of ACR9 with FXa..... | 283 |
| 6.2.11 Surface plasmon resonance (SPR) analysis to demonstrate binding of ACR9 to thrombin..... | 283 |
| 6.2.12 <i>In vitro</i> cytotoxicity of ACR9..... | 284 |
| 6.2.12.1 Effect of ACR9 on mammalian erythrocytes..... | 284 |
| 6.2.12.2 Effect of ACR9 on mammalian cells by MTT assay..... | 285 |
| 6.2.12.3 Effect of ACR9 on cell cycle by flow cytometry analysis..... | 285 |
| 6.2.13 Assessment of <i>in vivo</i> toxicity of ACR9..... | 286 |
| 6.2.13.1 Effect on survival and behavioral parameters..... | 286 |
| 6.2.13.2 Effect on serological parameters..... | 286 |
| 6.2.13.3 Effect on blood parameters..... | 286 |
| 6.2.13.4 Effect on histological parameters..... | 289 |
| 6.2.14 <i>In vivo</i> therapeutic property of ACR9..... | 290 |
| 6.2.14.1 <i>In vivo</i> anticoagulant property of ACR9..... | 290 |
| 6.2.14.2 <i>In vivo</i> antithrombotic property of ACR9..... | 290 |
| 6.3 Discussion..... | 293 |
| Bibliography..... | 295 |
| <hr/> | |
| Chapter VII | |
| CONCLUSIONS AND FUTURE PERSPECTIVES | 301-303 |
| 7.1 Conclusions and future perspectives..... | 301 |
| <hr/> | |
| Publications and Patents | 304-306 |
| <hr/> | |
| Awards received in National Conferences and Seminars/Other Awards | 307 |
| <hr/> | |